US Patent Issued to Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Leon Berard on Oct. 7 for "Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy" (French Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,838, issued on Oct. 7, was assigned to Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris), Centre National de la Recherche Scientifique (CNRS) (Paris), Universite Claude Bernard Lyon 1 (Villeurbanne, France), Hospices Civils de Lyon (Lyons, France) and Centre Leon Berard (Lyons, France).

"Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy" was invented by Charles Dumontet (Venissieux, France) and Abdelkamel Chettab (Lyons, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a pharmaceutical combination product comprisi...